These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 5530987)

  • 1. [Relation between viremia and sero-antibodies to the anti-yellow fever vaccination of persons vaccinated with strain 17D-EP].
    Santiago Actis A; Sa Fleitas MJ
    Rev Sanid Milit Argent; 1970; 69(1):51-63. PubMed ID: 5530987
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection.
    Reinhardt B; Jaspert R; Niedrig M; Kostner C; L'age-Stehr J
    J Med Virol; 1998 Oct; 56(2):159-67. PubMed ID: 9746073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
    Collaborative Group for Studies with Yellow Fever Vaccine
    Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
    Barrett AD; Teuwen DE
    Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yellow fever outbreak in Ipetu-Ijesa: response after mass vaccination.
    Adu FD; Adeniji JA; Tomori O; Adelasoye A
    Rev Roum Virol; 1993; 44(1-2):3-7. PubMed ID: 8043476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocytes and yellow fever. I. Transient virus refractory state following vaccination of man with the 17-D strain.
    Wheelock EF; Toy ST; Stjernholm RL
    J Immunol; 1970 Nov; 105(5):1304-6. PubMed ID: 5496134
    [No Abstract]   [Full Text] [Related]  

  • 7. [Yellow fever].
    Wiercińska-Drapało A
    Przegl Epidemiol; 2004; 58 Suppl 1():101-5. PubMed ID: 15807166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yellow fever-associated viscerotropic disease in Barcelona, Spain.
    Muñoz J; Vilella A; Domingo C; Nicolas JM; de Ory F; Corachan M; Tenorio A; Gascon J
    J Travel Med; 2008; 15(3):202-5. PubMed ID: 18494699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
    Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
    Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice.
    van der Most RG; Harrington LE; Giuggio V; Mahar PL; Ahmed R
    Virology; 2002 Apr; 296(1):117-24. PubMed ID: 12036323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yellow fever outbreak in Ipetu-Ijesa: response after mass vaccination.
    Adu FD; Adeniji JA; Tomori O; Adelasoye A
    Rom J Virol; 1993; 44(1-2):3-7. PubMed ID: 9702244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine.
    GROOT H; RIBERIRO RB
    Bull World Health Organ; 1962; 27(6):699-707. PubMed ID: 13950710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005.
    Fernandes GC; Camacho LA; Sá Carvalho M; Batista M; de Almeida SM
    Vaccine; 2007 Apr; 25(16):3124-8. PubMed ID: 17316927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Epidemic of yellow fever in the southeastern region of Upper Volta (October-December, 1983). Epidemiological study. Preliminary results].
    Roux J; Baudon D; Robert V; Stanghellini A; Gazin P; Lhuillier M; Saluzzo JF; Cornet M; Sarthou JL; Molez JF
    Med Trop (Mars); 1984; 44(4):303-9. PubMed ID: 6542965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination.
    Martins MA; Silva ML; Elói-Santos SM; Ribeiro JG; Peruhype-Magalhães V; Marciano AP; Homma A; Kroon EG; Teixeira-Carvalho A; Martins-Filho OA
    Vaccine; 2008 Feb; 26(9):1173-84. PubMed ID: 18243433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases.
    Receveur MC; Thiébaut R; Vedy S; Malvy D; Mercié P; Bras ML
    Clin Infect Dis; 2000 Sep; 31(3):E7-8. PubMed ID: 11017859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The known and the unknown in yellow fever ecology and epidemiology.
    Downs WG
    Ecol Dis; 1982; 1(2-3):103-10. PubMed ID: 6148230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WHO Expert Committee on Yellow Fever. Third report.
    World Health Organ Tech Rep Ser; 1971; 479():1-56. PubMed ID: 5003432
    [No Abstract]   [Full Text] [Related]  

  • 19. [Epidemiology of hepatitis A and B and yellow fever in Zaire].
    Werner GT; Fresenius K; Frösner GG; Huber HC
    Fortschr Med; 1984 Oct; 102(40):1019-21. PubMed ID: 6334010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yellow fever vaccines and international travelers.
    Barnett ED; Wilder-Smith A; Wilson ME
    Expert Rev Vaccines; 2008 Jul; 7(5):579-87. PubMed ID: 18564013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.